Syros Pharmaceuticals (SYRS) Competitors $0.18 +0.01 (+3.12%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.17 0.00 (-1.26%) As of 01/31/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SYRS vs. TENX, ATHE, ALLK, CARM, COCP, MRKR, APRE, SNTI, ATHA, and LIANShould you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Tenax Therapeutics (TENX), Alterity Therapeutics (ATHE), Allakos (ALLK), Carisma Therapeutics (CARM), Cocrystal Pharma (COCP), Marker Therapeutics (MRKR), Aprea Therapeutics (APRE), Senti Biosciences (SNTI), Athira Pharma (ATHA), and LianBio (LIAN). These companies are all part of the "pharmaceutical products" industry. Syros Pharmaceuticals vs. Tenax Therapeutics Alterity Therapeutics Allakos Carisma Therapeutics Cocrystal Pharma Marker Therapeutics Aprea Therapeutics Senti Biosciences Athira Pharma LianBio Tenax Therapeutics (NASDAQ:TENX) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings. Which has more risk and volatility, TENX or SYRS? Tenax Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Do institutionals & insiders hold more shares of TENX or SYRS? 1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 3.7% of Tenax Therapeutics shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has better valuation & earnings, TENX or SYRS? Tenax Therapeutics has higher earnings, but lower revenue than Syros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenax TherapeuticsN/AN/A-$7.71MN/AN/ASyros Pharmaceuticals$9.94M0.47-$164.57M-$3.03-0.06 Does the MarketBeat Community favor TENX or SYRS? Syros Pharmaceuticals received 223 more outperform votes than Tenax Therapeutics when rated by MarketBeat users. Likewise, 62.41% of users gave Syros Pharmaceuticals an outperform vote while only 56.03% of users gave Tenax Therapeutics an outperform vote. CompanyUnderperformOutperformTenax TherapeuticsOutperform Votes14456.03% Underperform Votes11343.97% Syros PharmaceuticalsOutperform Votes36762.41% Underperform Votes22137.59% Do analysts recommend TENX or SYRS? Tenax Therapeutics currently has a consensus price target of $16.00, suggesting a potential upside of 166.67%. Syros Pharmaceuticals has a consensus price target of $3.33, suggesting a potential upside of 1,802.59%. Given Syros Pharmaceuticals' higher possible upside, analysts clearly believe Syros Pharmaceuticals is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media refer more to TENX or SYRS? In the previous week, Syros Pharmaceuticals had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 4 mentions for Syros Pharmaceuticals and 3 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.62 beat Syros Pharmaceuticals' score of 0.09 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syros Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is TENX or SYRS more profitable? Tenax Therapeutics' return on equity of -46.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tenax TherapeuticsN/A -46.00% -42.65% Syros Pharmaceuticals N/A -3,369.56%-97.04% SummaryTenax Therapeutics beats Syros Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition Export to ExcelMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.12M$6.86B$5.58B$9.11BDividend YieldN/A2.90%5.32%3.99%P/E Ratio-0.069.6789.2618.26Price / Sales0.47301.931,254.4080.65Price / CashN/A73.5045.9637.70Price / Book0.225.275.124.70Net Income-$164.57M$136.98M$111.40M$224.47M7 Day Performance-17.08%-0.73%2.33%-0.20%1 Month Performance-23.76%0.16%3.20%0.57%1 Year Performance-97.54%7.59%24.64%20.29% Syros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros Pharmaceuticals4.2001 of 5 stars$0.18+3.1%$3.33+1,802.6%-97.5%$5.12M$9.94M-0.06120Analyst ForecastShort Interest ↑News CoverageTENXTenax Therapeutics1.9844 of 5 stars$6.36-2.8%$16.00+151.6%-52.9%$21.69MN/A0.009News CoverageATHEAlterity Therapeutics3.0414 of 5 stars$2.97+1.0%$6.00+102.0%+127.5%$21.68MN/A0.0010Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageALLKAllakos4.4262 of 5 stars$0.24-80.2%$2.00+733.3%-81.1%$21.44MN/A-0.12190High Trading VolumeCARMCarisma Therapeutics4.2031 of 5 stars$0.51+6.3%$4.94+876.3%-78.1%$21.13M$14.92M-0.3220Short Interest ↓News CoverageCOCPCocrystal Pharma3.6013 of 5 stars$2.04-3.6%$7.00+244.0%+24.3%$20.70MN/A-1.1010Short Interest ↓Gap DownMRKRMarker Therapeutics4.1551 of 5 stars$1.93-9.9%$19.00+885.0%-60.3%$20.66M$3.31M0.0060Short Interest ↑News CoverageHigh Trading VolumeAPREAprea Therapeutics3.2635 of 5 stars$3.79-9.8%$15.50+309.0%-24.4%$20.58M$580,000.00-1.357Short Interest ↓Positive NewsSNTISenti Biosciences3.3386 of 5 stars$4.48-5.1%$10.00+123.2%-3.1%$20.56M$2.56M-0.294Short Interest ↓Gap UpATHAAthira Pharma3.2007 of 5 stars$0.52-5.8%$13.83+2,545.0%-83.4%$20.22MN/A-0.1840Short Interest ↓High Trading VolumeLIANLianBioN/A$0.19-19.5%N/A-95.1%$20.00MN/A-0.23110News CoverageGap Up Related Companies and Tools Related Companies TENX Alternatives ATHE Alternatives ALLK Alternatives CARM Alternatives COCP Alternatives MRKR Alternatives APRE Alternatives SNTI Alternatives ATHA Alternatives LIAN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SYRS) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRS Stock Alerts